Clinical Trials

120 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03675737 2026-02-27

KEYNOTE-859

1,579 enrolled 31 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03713593 2026-02-05

LEAP-002

794 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03867084 2026-02-04

KEYNOTE-937

959 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

90 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 6 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

94 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03062358 2025-09-30

MK-3475-394

453 enrolled 22 charts

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT02628067 2025-09-22

KEYNOTE 158

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05064059 2025-09-17

MK-4280A-007

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

Phase 1 Completed

116 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03631407 2024-11-21

MK-7690-046

41 enrolled 20 charts

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04210115 2024-11-15

KEYNOTE 975

703 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03189719 2024-10-15

KEYNOTE-590

749 enrolled 40 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

307 enrolled 16 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT02702414 2024-09-04

KEYNOTE-224

156 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT02834052 2024-06-07

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Phase 1/2 Completed

42 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colonic Neoplasms

NCT02460198 2023-07-27

KEYNOTE-164

124 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05281003 2023-07-13

HYPERION

Phase 2 Recruiting

128 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Hypoxia, Digestive System Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT02494583 2023-04-13

MK-3475-062

763 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03019588 2023-03-30

MK-3475-063

Phase 3 Terminated

94 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03933449 2023-03-29

KEYNOTE-181

123 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

628 enrolled 27 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Unknown

54 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT02702401 2022-09-29

KEYNOTE-240

413 enrolled 22 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT02559687 2022-09-14

KEYNOTE-180

121 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

318 enrolled 24 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04859582 2021-12-16

KEYNOTE-859

Phase 3 Withdrawn